It was reported, that the implantable cardioverter defibrillator (icd) system oversensed far-field ventricular signals in the atrial channel.Leading to inappropriate atrial tachy response (atr) episodes.Boston scientific technical services (ts) reviewed the recorded episodes, and indicated the majority of the far-field signals are not falling into the programmed blanking periods.Additionally, the amplitude of the right atrial (ra) lead exhibited a significative decrease since implant.The ra lead is a not a boston scientific device.Ts recommended adjusting the blanking periods.Testing the atrial lead integrity in clinic by isometric testing and comparing the current position of the lead versus the implant position.The field representative communicated the suggestions to the physician.At this time, no adverse patient effects have been reported.And the system remains in service.This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|